Journey Medical Corporation Announces Expanded Payer Coverage for Emrosi™
Payer Coverage Expansion: Journey Medical Corporation announced that payer coverage for its rosacea treatment, Emrosi™, has increased to 65% of commercial lives in the U.S., up from 29% in May 2025, which is expected to boost prescription demand.
Emrosi™ Overview and Market Impact: Emrosi™ is an FDA-approved medication for treating inflammatory lesions of rosacea in adults, with strong clinical data supporting its efficacy, and the company aims to make it the standard of care for rosacea treatment.
Trade with 70% Backtested Accuracy
Analyst Views on DERM
About DERM
About the author
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.
Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.
Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.
Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.
Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.
Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.
Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.
Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).
HC Wainwright & Co. Begins Coverage of Journey Medical with a Buy Rating and Sets Price Target at $13
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open
Emerging Growth Conference Announcement: The 85th Emerging Growth Conference is scheduled for August 20 & 21, 2025, focusing on companies with strong management and growth potential across various sectors.
Day 1 Schedule Highlights: Keynote speakers include CEOs from companies such as Immuron Limited, Nutriband, Inc., and Journey Medical Corporation, presenting their innovative products and strategies.
Day 2 Schedule Highlights: Presentations will feature executives from Eshallgo, Inc., Grove Collaborative Holdings, Inc., and U.S. Energy Corporation, among others, discussing their business developments.
Engagement and Participation: Attendees can register for the conference, submit questions to presenting companies, and access replays via the EmergingGrowth.com platform.
Journey Medical Corporation to Showcase at the Emerging Growth Conference
Company Overview: Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions.
Upcoming Presentation: CEO Claude Maraoui will present a corporate overview at the Emerging Growth Conference on August 20, 2025, at 12:35 p.m. ET, via virtual video webcasts.
Product Portfolio: The company currently markets eight branded prescription drugs aimed at treating common skin conditions, leveraging an efficient sales and marketing model.
Contact Information: For more details, interested parties can visit the company's website or contact their media relations team directly.
Journey Medical (DERM) Q3 Earnings: Analyzing Key Metrics Against Estimates
Journey Medical Corporation Financial Performance: For Q3 2025, Journey Medical Corporation reported a revenue of $17.63 million, a 20.5% increase year-over-year, but fell short of the Zacks Consensus Estimate by 0.39%. The EPS was -$0.09, slightly better than the previous year's -$0.12 but below the consensus estimate of -$0.08.
Investor Insights: Investors are closely monitoring revenue and earnings changes to gauge the company's financial health, with key metrics providing a clearer picture of performance compared to year-ago numbers and analyst estimates.
Technological Advancements in Investment: The article highlights the transformative impact of artificial intelligence and its potential convergence with quantum computing, suggesting significant wealth-building opportunities for investors.
Investment Recommendations: A special report titled "Beyond AI: The Quantum Leap in Computing Power" is mentioned, offering insights into stocks poised to benefit from advancements in quantum computing, along with a free report on the "7 Best Stocks for the Next 30 Days."
Journey Medical Corporation Presents Efficacy Data Analysis from Combined Emrosi™ (DFD-29) Phase 3 Clinical Trial at the 2025 Fall Clinical Dermatology Conference
FDA Approval and Efficacy: Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) is FDA-approved for treating inflammatory lesions of rosacea in adults, showing superior efficacy in clinical trials compared to both placebo and doxycycline.
Clinical Trial Results: In a pooled analysis of two Phase 3 trials, 62.7% of subjects treated with DFD-29 achieved treatment success, significantly outperforming the 39.0% success rate of Oracea and 28.2% for placebo, with notable reductions in inflammatory lesions.
Safety Profile: DFD-29 was well tolerated in trials, with no major safety issues reported, and the incidence of treatment-emergent adverse events was comparable across all treatment groups.
Market Position and Commitment: Journey Medical Corporation aims to expand Emrosi's market presence, emphasizing its potential as a standard treatment for rosacea and its commitment to improving patient outcomes in dermatology.
Journey Medical Releases Combined Phase 3 Data for Emrosi in Treating Rosacea
Clinical Data Presentation: Journey Medical Corporation presented pooled Phase 3 data for DFD-29 (Emrosi) at the 2025 Fall Clinical Dermatology Conference, focusing on its efficacy in treating inflammatory lesions of rosacea in adults.
Efficacy Results: The analysis showed that 62.7% of patients treated with DFD-29 achieved treatment success, significantly outperforming the Oracea group (39.0%) and the placebo group (28.2%).
HC Wainwright & Co. Begins Coverage of Journey Medical with a Buy Rating and Sets Price Target at $13
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, sharing strategies and intelligence.
Market Winning Tool: Traders utilize Benzinga Pro's resources to enhance their trading success in the stock market.
Join the Live Stream of Day 1 at the Emerging Growth Conference 85 on August 20; Registration Now Open
Emerging Growth Conference Announcement: The 85th Emerging Growth Conference is scheduled for August 20 & 21, 2025, focusing on companies with strong management and growth potential across various sectors.
Day 1 Schedule Highlights: Keynote speakers include CEOs from companies such as Immuron Limited, Nutriband, Inc., and Journey Medical Corporation, presenting their innovative products and strategies.
Day 2 Schedule Highlights: Presentations will feature executives from Eshallgo, Inc., Grove Collaborative Holdings, Inc., and U.S. Energy Corporation, among others, discussing their business developments.
Engagement and Participation: Attendees can register for the conference, submit questions to presenting companies, and access replays via the EmergingGrowth.com platform.
Journey Medical Corporation to Showcase at the Emerging Growth Conference
Company Overview: Journey Medical Corporation is a commercial-stage pharmaceutical company focused on marketing FDA-approved prescription products for dermatological conditions.
Upcoming Presentation: CEO Claude Maraoui will present a corporate overview at the Emerging Growth Conference on August 20, 2025, at 12:35 p.m. ET, via virtual video webcasts.
Product Portfolio: The company currently markets eight branded prescription drugs aimed at treating common skin conditions, leveraging an efficient sales and marketing model.
Contact Information: For more details, interested parties can visit the company's website or contact their media relations team directly.
